The New York Times is reporting that the vaccine--an often painful series of 3 shots given over a period of 7 months--has only been taken by 1 in 4 American girls under age 18, and is not routinely recommended by pediatricians. But new research is showing the vaccine to have potential benefits for men, specifically protection against cancers of the anus and penis, that might warrant it becoming routine for boys.
From the Times article:
Yet a growing body of evidence implicates the human papillomavirus in a wide range of equal-opportunity cancers that don't discriminate based on gender.
HPV strains 16 and 18, which the vaccine protects against, have been linked to anal cancer, penile cancer and common cancers of the back of the throat and tonsils, where the virus can spread through oral sex.
Merck, which makes Gardasil, is trying to muster enthusiasm for the vaccine with new data suggesting that the vaccine may protect against anal cancer and, possibly, other cancers as well. The research may soon tip the scales in favor of a national recommendation to make male vaccination routine.
New data from a Merck clinical trial that included several hundred men who have sex with men indicate that three years after vaccination, those who received Gardasil were significantly less likely to have developed high-grade precancerous anal lesions than a comparison group. Only three of the 194 men who were vaccinated developed the abnormalities, compared with 13 of 208 men who received placebo shots.
Debbie Saslow, director for breast and gynecological cancers at the American Cancer Society, said that even though the numbers are small, "the data are believable."
The vaccine has been tested for safety in just 1,000 boys younger than 16. In a trial of 4,055 young men ages 16 to 26, the most common side effects were headache, fever and pain, itching, redness, swelling and bruising.